GlassScriptPhysician profile
Smriti Goel
NPI 1972559516
$5,373.62
in general payments reported to CMS, 2019-2025
26 companies · $853 in 2025
The $853 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $754 · 2020: $636 · 2021: $1,060 · 2022: $550 · 2023: $720 · 2024: $801 · 2025: $853.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,374.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,373.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $836.38 | 2019-2025 | Farxiga, Airsupra |
| Amgen INC. | $697.92 | 2019-2024 | Repatha, Otezla, Krystexxa |
| Pfizer INC. | $599.17 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $464.98 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Advanced Respiratory, INC | $360.00 | 2021 | |
| Lilly USA, LLC | $335.46 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $324.34 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Amarin Pharma, INC. | $227.76 | 2019-2022 | |
| Abbott Laboratories | $207.69 | 2022-2025 | Freestyle Libre 3 |
| Mylan Specialty L.P. | $187.49 | 2022-2024 | Yupelri |
| Abbvie INC. | $169.82 | 2019-2024 | |
| Medline Industries LP | $167.74 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $137.64 | 2020-2023 | Eliquis |
| Janssen Pharmaceuticals, INC | $120.41 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $104.20 | 2019-2024 | Livalo |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $78.94 | 2025 | Yupelri |
| Novartis Pharmaceuticals Corporation | $65.45 | 2019-2022 | |
| Boston Scientific Corporation | $59.66 | 2023-2025 | Watchman Access System, Watchman Flx |
| Sunovion Pharmaceuticals INC. | $49.47 | 2020 | |
| Allergan, INC. | $35.49 | 2020 | |
| Horizon Therapeutics Plc | $34.21 | 2019-2023 | Krystexxa |
| Takeda Pharmaceuticals U.S.A., INC. | $30.49 | 2021 | |
| Organogenesis INC. | $26.10 | 2022-2023 | Puraply |
| Glaxosmithkline, LLC. | $21.13 | 2025 | Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $18.14 | 2023 | Rexulti |
| Echosens North America, INC. | $13.54 | 2025 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Smriti Goel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.